RETRA: evaluating the transfusion rate with darbepoetin alfa 500 µg every 3 weeks in anaemic cancer patients receiving chemotherapy

References

• Ludwig H, Strasser K. Symptomatology of anemia. Semin Oncol 2001;28(2 Suppl 8):7-14
   PubMed Web of Science ®Google Scholar
• Aapro MS, Link H. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. Oncologist 2008;13(Suppl 3):33-6
   PubMed Web of Science ®Google Scholar
• Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999;91:1616-34
   PubMed Web of Science ®Google Scholar
• Barrett-Lee PJ, Ludwig H, Birgegard G, et al. Independent risk factors for anemia in cancer patients receiving chemotherapy: results from the European Cancer Anaemia Survey. Oncology 2006;70:34-48
   PubMed Web of Science ®Google Scholar
• Tchekmedyian NS. Anemia in cancer patients: significance, epidemiology, and current therapy. Oncology (Williston Park) 2002;16(9 Suppl 10):17-24
   PubMed Web of Science ®Google Scholar
• Birgegård G, Gascón P, Ludwig H. Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European CANCER ANAEMIA SURVEY. Eur J Haematol 2006;77:378-86
   PubMed Web of Science ®Google Scholar
• Spivak JL, Gascon P, Ludwig H. Anemia management in oncology and hematology. Oncologist 2009;14(Suppl 1):43-56
   PubMed Web of Science ®Google Scholar
• Coiffier B, Guastalla JP, Pujade-Lauraine E, et al. Predicting cancer-associated anaemia in patients receiving non-platinum chemotherapy: results of a retrospective survey. Eur J Cancer 2001;37:1617-23
   PubMed Web of Science ®Google Scholar
• Caro JJ, Salas M, Ward A, et al. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001;91:2214-21
   PubMed Web of Science ®Google Scholar
• Taylor RW, O'Brien J, Trottier SJ, et al. Red blood cell transfusions and nosocomial infections in critically ill patients. Crit Care Med 2006;34:2302-8; quiz 9
   PubMed Web of Science ®Google Scholar
• Goodnough LT. Risks of blood transfusion. Crit Care Med 2003;31(12 Suppl):S678-86
   Google Scholar
• Madjdpour C, Spahn DR. Allogeneic red blood cell transfusions: efficacy, risks, alternatives and indications. Br J Anaesth 2005;95:33-42
   PubMed Web of Science ®Google Scholar
• Spiess BD. Red cell transfusions and guidelines: a work in progress. Hematol Oncol Clin North Am 2007;21:185-200
   PubMed Web of Science ®Google Scholar
• Koch CG, Li L, Sessler DI, et al. Duration of red-cell storage and complications after cardiac surgery. N Engl J Med 2008;358:1229-39
   PubMed Web of Science ®Google Scholar
• Murphy GJ, Reeves BC, Rogers CA, et al. Increased mortality, postoperative morbidity, and cost after red blood cell transfusion in patients having cardiac surgery. Circulation 2007;116:2544-52
   PubMed Web of Science ®Google Scholar
• Bernard AC, Davenport DL, Chang PK, et al. Intraoperative transfusion of 1U to 2U packed red blood cells is associated with increased 30-day mortality, surgical-site infection, pneumonia, and sepsis in general surgery patients. J Am Coll Surg 2009;208:931-7, 7 e1-2; discussion 8-9
   PubMed Web of Science ®Google Scholar
• Koch CG, Li L, Van Wagoner DR, et al. Red cell transfusion is associated with an increased risk for postoperative atrial fibrillation. Ann Thorac Surg 2006;82:1747-56
   PubMed Web of Science ®Google Scholar
• Engoren MC, Habib RH, Zacharias A, et al. Effect of blood transfusion on long-term survival after cardiac operation. Ann Thorac Surg 2002;74:1180-6
   PubMed Web of Science ®Google Scholar
• Hebert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 1999;340:409-17
   PubMed Web of Science ®Google Scholar
• Mikhael J, Melosky B, Cripps C, et al. Canadian supportive care recommendations for the management of anemia in patients with cancer. Curr Oncol 2007;14:209-17
   PubMedGoogle Scholar
• Rodgers GM 3rd, Becker PS, Bennett CL. Cancer- and chemotherapy-induced anemia. J Natl Compr Canc Netw 2008;6:536-64
   PubMedGoogle Scholar
• Scrijvers D, Roila F. Erythropoiesis-stimulating agents in cancer patients: ESMO recommendations for use. Ann Oncol 2009;20(Suppl 4):159-61
   PubMedGoogle Scholar
• Rizzo JD, Somerfield MR, Hagerty KL, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. Blood 2008;111:25-41
   PubMed Web of Science ®Google Scholar
• Aapro M, Ludwig H, Bokemeyer C, et al. Modeling of treatment response to erythropoiesis-stimulating agents as a function of center- and patient-related variables: results from the Anemia Cancer Treatment (ACT) study. Ann Oncol 2009;20:1714-21
   PubMed Web of Science ®Google Scholar
• Egrie JC, Dwyer E, Browne JK, et al. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 2003;31:290-9
   PubMed Web of Science ®Google Scholar
• Glaspy J, Henry D, Patel R, et al. Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: a randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa. Eur J Cancer 2005;41:1140-9
   PubMed Web of Science ®Google Scholar
• Canon JL, Vansteenkiste J, Bodoky G, et al. Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia. J Natl Cancer Inst 2006;98:273-84
   PubMed Web of Science ®Google Scholar
• Luo W, Nordstrom BL, Fraeman K, et al. Adherence to guidelines for use of erythropoiesis-stimulating agents in patients with chemotherapy-induced anemia: results of a retrospective study of an electronic medical-records database in the United States, 2002-2006. Clin Ther 2008;30:2423-35
   PubMed Web of Science ®Google Scholar
• Ludwig H, Aapro M, Bokemeyer C, et al. Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: findings from the Anaemia Cancer Treatment (ACT) study. Eur J Cancer 2009;45:1603-15
   PubMed Web of Science ®Google Scholar
• Pat K, Anrys B, Verhulst D, et al. Observational Aranesp Survey to Investigate the Q3W Schedule (OASIS): a prospective observational study of treatment of chemotherapy-induced anaemia with every 3 weeks darbepoetin alfa. Support Care Cancer 2009;17:211-15
   PubMed Web of Science ®Google Scholar
• Adams JR, Elting LS, Lyman GH, et al. Use of erythropoietin in cancer patients: assessment of oncologists' practice patterns in the United States and other countries. Am J Med 2004;116:28-34
   PubMed Web of Science ®Google Scholar
• Van Belle S, Dalivoust P, Reinthaller A, et al. CHOICE, an international, observational study to examine current practice use of darbepoetin alfa in the management of chemotherapy-induced anaemia. Eur J Integrative Med 2009;1:226
   Google Scholar
• Van Belle S, Dalivoust P, Reinthaller A, et al. Current practice use of darbepoetin alfa in the management of chemotherapy-induced anaemia in patients <65 and ≥65 years: interim data from CHOICE, an international, observational study. Crit Rev Oncol Hematol 2009;72:51-2
   Google Scholar
• Hershman DL, Buono DL, Malin J, et al. Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer. J Natl Cancer Inst 2009;101:1633-41
   PubMed Web of Science ®Google Scholar
• Ludwig H, Van Belle S, Barrett-Lee P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004;40:2293-306
   PubMed Web of Science ®Google Scholar
• Vansteenkiste J, Hedenus M, Gascon P, et al. Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level <10 g/dL versus > or =10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial. BMC Cancer 2009;9:311
   PubMed Web of Science ®Google Scholar